RecruitingPhase 3NCT06464146

Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine

Pain Reduction for Limb Injuries in Pediatric Emergency Departments: A Randomised Clinical Trial Comparing Intranasal Fentanyl or Intranasal Ketamine to Oral Morphine


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

300 participants

Start Date

Feb 26, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to determine if IN fentanyl (1.5 µg/kg) or IN ketamine (1 mg/kg) is more effective at 30 minutes than oral morphine (0.5 mg/kg) in reduction of moderate and severe pain associated with limb injuries in patients 2-17 years of age presenting to the ED.


Eligibility

Min Age: 2 YearsMax Age: 17 Years

Inclusion Criteria7

  • Child aged 2 years to 17 years and 11 months
  • With 10 kg ≤ Weight ≤ 100 kg
  • Presenting to ED with a traumatic pain and suspected fracture(s) based on an acute deformity AND experiencing pain and/or functional impotence in the injured limb(s)
  • Within the first 12 hours after the injury
  • VAS pain score at ED arrival ≥ 60/100 (if child ≥ 7 years) or Evendol pain score at ED arrival ≥ 7/15 (if child < 7 years)
  • Affiliated to health insurance
  • At least one signed parental informed consent

Exclusion Criteria16

  • Received narcotic pain medication prior to arrival
  • Contraindication to morphine, mentioned in SmPC
  • Hypersensitivity to ketamine or fentanyl or to excipients (sodium chloride, sodium hydroxide), or to other opioids.
  • Contraindication to fentanyl or ketamine, mentioned in SmPC
  • GCS <15
  • Evidence of significant femur, head, chest, abdominal, or spine injury
  • Open fracture
  • Nasal trauma or complete nasal obstruction
  • Active epistaxis
  • Nasal or sinus surgery within 6 months before inclusion
  • History of high blood pressure, known coronary artery disease, congestive heart failure, acute glaucoma, increased intracranial pressure, major psychiatric disorder, hepatocellular insufficiency
  • Active or history of psychiatric disorder
  • Known pregnancy or suspicion of being pregnant
  • Breastfeeding
  • Non-French speaking parent and / or child.
  • Participation to another interventional clinical research

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMorphine

oral morphine (0.5 mg / kg)

DRUGIN fentanyl

IN fentanyl (1.5 µg/kg)

DRUGIN ketamine

IN ketamine (1 mg/kg)

DRUGNaCl 0,9 %

Injectable solution used as Placebo of Oral morphine or IN fentanyl/ ketamine.


Locations(5)

Ambroise Paré Hospital

Boulogne-Billancourt, France

Roger Salengro Hospital

Lille, France

Timone Hospital

Marseille, France

Mère-Enfant Hospital

Nantes, France

Hopital Necker Enfants malades

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06464146


Related Trials